 | | Vol. 8.13 – 18 April, 2022 |
| |
|
|
| Scientists utilized the phenomenon that chronic wounds possessed an elevated local pH of 8.9 and developed pH-sensitive silica nanoparticles to achieve a targeted drug release on alkaline wounds and optimize drug utility.
[Acta Biomaterialia] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| | DERMAL STEM CELLS & TISSUE REGENERATION |
|
|
|
| Investigators studied the proteins present in primary skin fibroblasts collected from 82 healthy individuals across a wide age spectrum who participated in the Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing study of the National Institute on Aging.
[Aging Cell] |
|
|
|
| Researchers conducted a retrospective cohort study of 350 subjects with hematologic disorders who underwent skin fibroblast culture for germline genetic testing.
[Human Mutation] |
|
|
|
| Cell proliferation capacity was higher in JAM-A-modified mouse fibroblasts. Elevated levels of basic fibroblast growth factor and epidermal growth factor were found in the JAM-A-modified group in vivo and in vitro.
[Cell Biology International] |
|
|
|
| Transcriptome comparisons of human dermal papilla cells in hair beads (HBs) culture and in typical 2D culture revealed that the phosphoinositide 3-kinase and Akt (PI3K/Akt) signaling pathway was significantly upregulated in HB culture.
[Journal of Bioscience and Bioengineering] |
|
|
|
| Researchers determined that keratinocytes exposed to cigarette smoke (CS) had increased oxidative damage evaluated by 4-HNE protein adduct and carbonyl formation.
[In Vitro Cellular & Developmental Biology – Animal] |
|
|
|
| Scientists found that ropivacaine delayed wound closure in vivo. In vitro experiments, it was demonstrated that ropivacaine significantly inhibited the proliferation and migration of HaCaT cells via the suppression of PI3K/AKT/mTOR signaling pathway.
[BMC Anesthesiology] |
| |
|
|
| Patients with confirmed pT3/4 head and neck cutaneous squamous cell carcinomas undergoing curative surgical resection between 2014-2020 were identified retrospectively from a prospectively maintained research database.
[Annals of Surgical Oncology] |
|
|
|
| The authors have screened a focused library of clinically used artemisinin-combination therapeutic antimalarials for the apoptotic elimination of cultured malignant melanoma cell lines.
[Molecular Carcinogenesis] |
|
|
|
| Investigators constructed retinoic acid-inducible gene I (RIG-I) knockout, RIG-I-overexpressing B16-F10 and RIG-I knockdown A375 melanoma cell lines, and analyzed the RIG-I-mediated change in the biological behavior of tumor cells.
[Human Cell] |
|
|
|
| Novel long non-coding RNA solute carrier organic anion transporter family member 4A1 antisense RNA 1 (SLCO4A1-AS1) was detected to be up-regulated in melanoma cell lines compared with human normal melanocytes.
[Experimental Dermatology] |
|
|
|
|
| Investigators summarize typical epithelial-mesenchymal signaling molecules and extracellular components under the control of follicular stem cells, aiming to broaden our current understanding of epithelial-mesenchymal interaction mechanisms in hair follicles regeneration and skin wound healing.
[Frontiers in Medicine] |
|
|
|
| To detect and prevent skin cancer earlier, the authors analyze whether atopic dermatitis is a risk factor for skin cancer.
[Dermatology and Therapy] |
|
|
|
|
| aTyr Pharma, Inc. announced that the FDA has granted the company orphan drug designation for its lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis.
[aTyr Pharma, Inc.] |
|
|
|
| Appili Therapeutics, Inc. announced the addition of ATI-1801, a clinical-stage topical paromomycin product to treat cutaneous leishmaniasis, to its development pipeline.
[Appili Therapeutics, Inc.] |
|
|
|
|
| June 20 – 23, 2022
Sevilla, Spain |
|
|
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
| | Helmholtz Munich – München, Germany |
|
|
|
| | Wellcome Sanger Institute – Cambridge, England, United Kingdom |
|
|
|
| | Brigham and Women’s Hospital – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
